Finally, BDTX-1535 is another inhibitor that is currently being explored in a first-in human clinical trial for patients with glioblastoma and NSCLC harboring sensitive EGFR alterations and who have disease progression following standard of care (NCT05256290). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.